Seroquel (Quetiapine) Age Indications
Seroquel is FDA-approved for adolescents aged 13–17 years for schizophrenia and for children and adolescents aged 10–17 years for acute manic episodes associated with bipolar I disorder; it is not approved for use in pediatric patients under 10 years of age. 1
FDA-Approved Pediatric Indications
Schizophrenia
- Approved for adolescents 13 years and older 12
- Efficacy established in one 6-week trial in adolescents aged 13–17 years 1
- Recommended dosing starts at 25 mg twice daily on Day 1, titrating to 400–800 mg/day by Day 5, with further adjustments in increments no greater than 100 mg/day 1
Bipolar I Disorder (Acute Manic Episodes)
- Approved for children and adolescents 10–17 years of age 123
- Efficacy established in one 3-week monotherapy trial in pediatric patients aged 10–17 years 1
- Can be used as monotherapy or as adjunct to lithium or divalproex 1
Adult Indications (Age 18+)
- Schizophrenia in adults 1
- Bipolar I disorder: acute manic episodes (monotherapy or adjunct), acute depressive episodes (monotherapy), and maintenance treatment (adjunct to lithium or divalproex) 1
Critical Age Restrictions
Seroquel is explicitly NOT approved for use in pediatric patients under 10 years of age. 11 This represents a hard lower age limit established by the FDA based on safety and efficacy data.
Important Pediatric Considerations
Diagnostic Requirements
- Pediatric schizophrenia and bipolar I disorder require thorough diagnostic evaluation before initiating medication therapy 1
- Symptom profiles can be variable in pediatric schizophrenia, and bipolar I disorder patients may have variable patterns of periodicity 1
- Medication should be part of a comprehensive treatment program including psychological, educational, and social interventions 1
Pediatric-Specific Monitoring
- Blood pressure must be measured at baseline and periodically during treatment in children and adolescents, as quetiapine can cause increased blood pressure in this population 1
- Standard metabolic monitoring (BMI, waist circumference, fasting glucose, lipid profile) applies to all age groups 4
Common Pitfall
Off-label use of low-dose quetiapine for insomnia in older adults (≥65 years) is associated with significantly increased risks of mortality, dementia, and falls compared to alternatives like trazodone 5. While not a pediatric concern, prescribers should recognize that quetiapine carries age-specific risks at both extremes of life—it is contraindicated under age 10 and carries substantial safety concerns in elderly populations, particularly those with dementia-related psychosis 1.